Generic Portfolio ErosionBoth glucagon and epinephrine are eroding faster than the Street was expecting, which analysts predict will lead to significant challenges.
Pipeline SetbacksThe company has faced continued setbacks on the pipeline front, including the two most recent CRLs on AMP-007 and AMP-018, which were key to offsetting erosion for the generic portfolio.
Revenue And Margin PressureAmphastar is facing several headwinds in 2025/2026, with anticipated significant revenue decline in Glucagon and a cautious outlook on epinephrine.